Targeted Sensitization of Glioblastoma Multiforme Using AAAPT Technology

Area of Science:

• Oncology
• Biotechnology
• Cancer Research

Background:

• Glioblastoma Multiforme (GBM) is an aggressive brain tumor with limited treatment options.
• Tumor recurrence is common due to therapy resistance, involving downregulation of cell death (CD95) and upregulation of survival (NF-κB) pathways.
• Current treatments can cause significant off-target toxicity to healthy tissues.

Purpose of the Study:

• To evaluate a novel priori activation of apoptosis pathways of tumor technology (AAAPT) for targeted GBM treatment.
• To assess AAAPT's efficacy in inducing GBM cell death and modulating survival/death pathways.
• To compare AAAPT's effectiveness and toxicity profile against standard GBM chemotherapy.

Main Methods:

• Treatment of GBM spheroids using AAAPT within 3D PEGDA microwells.
• Analysis of cell death pathways (e.g., CD95) and survival pathways (e.g., NF-κB).
• Comparison with Temozolomide (TMZ), a standard chemotherapy agent for GBM.

Main Results:

• AAAPT treatment led to increased GBM cell death in 3D spheroids.
• AAAPT upregulated cell death pathways and downregulated cell survival pathways.
• Compared to TMZ, AAAPT demonstrated enhanced efficacy in targeting GBM cells.

Conclusions:

• AAAPT offers a promising targeted approach to increase glioblastoma treatment efficacy.
• This technology has the potential to reduce off-target toxicity associated with conventional chemotherapy.
• AAAPT sensitizers may provide a viable alternative for GBM treatment, improving patient outcomes.